De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Amicus Therapeutics Beheer
Beheer criteriumcontroles 4/4
De CEO Amicus Therapeutics' is Brad Campbell, benoemd in Jan2015, heeft een ambtstermijn van 9.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.20M, bestaande uit 8.5% salaris en 91.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 9.47M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.6 jaar en 6.2 jaar.
Belangrijke informatie
Brad Campbell
Algemeen directeur
US$8.2m
Totale compensatie
| Percentage CEO-salaris | 8.5% |
| Dienstverband CEO | 9.8yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 7.6yrs |
| Gemiddelde ambtstermijn bestuur | 6.2yrs |
Recente managementupdates
Recent updates
'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?
May 06Amicus Therapeutics: An Inflection Point In Growth
Apr 27Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$147m |
| Dec 31 2023 | US$8m | US$699k | -US$152m |
| Sep 30 2023 | n/a | n/a | -US$174m |
| Jun 30 2023 | n/a | n/a | -US$185m |
| Mar 31 2023 | n/a | n/a | -US$204m |
| Dec 31 2022 | US$9m | US$591k | -US$237m |
| Sep 30 2022 | n/a | n/a | -US$264m |
| Jun 30 2022 | n/a | n/a | -US$281m |
| Mar 31 2022 | n/a | n/a | -US$270m |
| Dec 31 2021 | US$5m | US$551k | -US$250m |
| Sep 30 2021 | n/a | n/a | -US$239m |
| Jun 30 2021 | n/a | n/a | -US$252m |
| Mar 31 2021 | n/a | n/a | -US$254m |
| Dec 31 2020 | US$5m | US$516k | -US$277m |
| Sep 30 2020 | n/a | n/a | -US$295m |
| Jun 30 2020 | n/a | n/a | -US$293m |
| Mar 31 2020 | n/a | n/a | -US$325m |
| Dec 31 2019 | US$4m | US$501k | -US$356m |
| Sep 30 2019 | n/a | n/a | -US$345m |
| Jun 30 2019 | n/a | n/a | -US$442m |
| Mar 31 2019 | n/a | n/a | -US$419m |
| Dec 31 2018 | US$3m | US$468k | -US$349m |
| Sep 30 2018 | n/a | n/a | -US$340m |
| Jun 30 2018 | n/a | n/a | -US$293m |
| Mar 31 2018 | n/a | n/a | -US$279m |
| Dec 31 2017 | US$2m | US$450k | -US$284m |
Compensatie versus markt: De totale vergoeding ($USD 8.20M ) Brad } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.75M ).
Compensatie versus inkomsten: De vergoeding van Brad is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Brad Campbell (48 yo)
9.8yrs
Tenure
US$8,202,366
Compensatie
Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 9.8yrs | US$8.20m | 0.30% $ 9.5m | |
| Chief Financial Officer | 1.2yrs | US$3.27m | 0.0048% $ 151.4k | |
| Chief Legal Officer & Corporate Secretary | 8.7yrs | US$4.08m | 0.064% $ 2.0m | |
| Chief People Officer | 6yrs | US$3.21m | 0.047% $ 1.5m | |
| Chief Development Officer | no data | US$3.67m | 0.081% $ 2.6m | |
| Chief Accounting Officer & Controller | 6.6yrs | geen gegevens | 0.025% $ 788.2k | |
| Chief Science Officer | no data | geen gegevens | geen gegevens | |
| Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Global Chief Compliance & Risk Officer | 9.2yrs | geen gegevens | geen gegevens | |
| Head of Global Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Patient Advocate | 9.1yrs | geen gegevens | geen gegevens | |
| Chief Program Officer | 4.4yrs | geen gegevens | geen gegevens |
7.6yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van FOLD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 6.3yrs | US$8.20m | 0.30% $ 9.5m | |
| Independent Director | 5.3yrs | US$391.25k | 0.026% $ 829.0k | |
| Independent Director | 3.8yrs | US$391.25k | 0.0099% $ 313.6k | |
| Independent Director | 18.3yrs | US$407.07k | 0.025% $ 799.6k | |
| Independent Director | 15yrs | US$401.25k | 0.017% $ 540.6k | |
| Chairman & Lead Independent Director | 20.8yrs | US$426.25k | 0.025% $ 799.6k | |
| Independent Director | 3.3yrs | US$390.00k | 0.0081% $ 256.4k | |
| Independent Director | 6.1yrs | US$397.50k | 0.025% $ 779.3k |
6.2yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van FOLD wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).